Efficacy and safety of bexagliflozin compared with dapagliflozin as an adjunct to metformin in Chinese patients with type 2 diabetes mellitus: A 24‐week, randomized, double‐blind, active‐controlled, phase 3 trial
Fuente:
Wiley Open Access
Guardado en:
| Autores principales: | , , , , , , , , , , , , , , |
|---|---|
| Formato: | Artículo Open Access |
| Publicado: |
Wiley
2024
|
| Materias: | |
| Acceso en línea: | |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| _version_ | 1867003979421974528 |
|---|---|
| author | Lingding Xie Jie Han Zhifeng Cheng Dexue Liu Jie Liu Chunrong Xu Wenli Sun Qingju Li Fang Bian Wei Zhang Jinyu Chen Qian Zhu Tara K. Thurber J. Paul Lock Bo Zhang |
| author_facet | Lingding Xie Jie Han Zhifeng Cheng Dexue Liu Jie Liu Chunrong Xu Wenli Sun Qingju Li Fang Bian Wei Zhang Jinyu Chen Qian Zhu Tara K. Thurber J. Paul Lock Bo Zhang Lingding Xie Jie Han Zhifeng Cheng Dexue Liu Jie Liu Chunrong Xu Wenli Sun Qingju Li Fang Bian Wei Zhang Jinyu Chen Qian Zhu Tara K. Thurber J. Paul Lock Bo Zhang |
| collection | Wiley Open Access |
| contents | Efficacy and safety of bexagliflozin compared with dapagliflozin as an adjunct to metformin in Chinese patients with type 2 diabetes mellitus: A 24‐week, randomized, double‐blind, active‐controlled, phase 3 trial Lingding Xie Jie Han Zhifeng Cheng Dexue Liu Jie Liu Chunrong Xu Wenli Sun Qingju Li Fang Bian Wei Zhang Jinyu Chen Qian Zhu Tara K. Thurber J. Paul Lock Bo Zhang Journal of Diabetes AbstractBackgroundBexagliflozin and dapagliflozin are sodium‐glucose cotransporter‐2 (SGLT2) inhibitors. No direct comparison of SGLT2 inhibitors in a randomized controlled trial has been reported to date.MethodsThis was a multicenter, randomized, double‐blind, active‐controlled trial comparing bexagliflozin to dapagliflozin for the treatment of type 2 diabetes mellitus in adults with disease inadequately controlled by metformin. Subjects (n = 406) were randomized to receive bexagliflozin (20 mg) or dapagliflozin (10 mg) plus metformin. The primary endpoint was noninferiority of bexagliflozin to dapagliflozin for the change in glycated hemoglobin (HbA1c) from baseline to week 24. Secondary endpoints included intergroup differences in fasting plasma glucose (FPG), 2‐h‐postprandial glucose (PPG), body weight, and systolic blood pressure (SBP) from baseline to week 24. The trial also evaluated the safety profiles.ResultsThe model‐adjusted mean change from baseline to week 24 HbA1c was −1.08% for bexagliflozin and −1.10% for dapagliflozin. The intergroup difference of 0.03% (95% confidence interval [CI] −0.14% to 0.19%) was below the prespecified margin of 0.4%, confirming the noninferiority of bexagliflozin. The changes from baseline in FPG, PPG, body weight, and SBP were −1.95 mmol/L, −3.24 mmol/L, −2.52 kg, and −6.4 mm Hg in the bexagliflozin arm and −1.87 mmol/L, −3.07 mmol/L, −2.22 kg, and −6.3 mm Hg in the dapagliflozin arm. Adverse events were experienced in 62.6% and 65.0% and serious adverse events affected 4.4% and 3.5% of subjects in the bexagliflozin and dapagliflozin arm, respectively.ConclusionsBexagliflozin showed nearly identical effects and a similar safety profile to dapagliflozin when used in Chinese patients on metformin.image 10.1111/1753-0407.13526 http://creativecommons.org/licenses/by/4.0/ |
| doi_str_mv | 10.1111/1753-0407.13526 |
| format | Artículo Open Access |
| id | wiley_oa_10_1111_1753_0407_13526 |
| institution | Wiley Open Access |
| license_str_mv | http://creativecommons.org/licenses/by/4.0/ |
| publishDate | 2024 |
| publisher | Wiley |
| record_format | wiley_oa |
| spellingShingle | Efficacy and safety of bexagliflozin compared with dapagliflozin as an adjunct to metformin in Chinese patients with type 2 diabetes mellitus: A 24‐week, randomized, double‐blind, active‐controlled, phase 3 trial Lingding Xie Jie Han Zhifeng Cheng Dexue Liu Jie Liu Chunrong Xu Wenli Sun Qingju Li Fang Bian Wei Zhang Jinyu Chen Qian Zhu Tara K. Thurber J. Paul Lock Bo Zhang Journal of Diabetes Efficacy and safety of bexagliflozin compared with dapagliflozin as an adjunct to metformin in Chinese patients with type 2 diabetes mellitus: A 24‐week, randomized, double‐blind, active‐controlled, phase 3 trial Lingding Xie Jie Han Zhifeng Cheng Dexue Liu Jie Liu Chunrong Xu Wenli Sun Qingju Li Fang Bian Wei Zhang Jinyu Chen Qian Zhu Tara K. Thurber J. Paul Lock Bo Zhang Journal of Diabetes AbstractBackgroundBexagliflozin and dapagliflozin are sodium‐glucose cotransporter‐2 (SGLT2) inhibitors. No direct comparison of SGLT2 inhibitors in a randomized controlled trial has been reported to date.MethodsThis was a multicenter, randomized, double‐blind, active‐controlled trial comparing bexagliflozin to dapagliflozin for the treatment of type 2 diabetes mellitus in adults with disease inadequately controlled by metformin. Subjects (n = 406) were randomized to receive bexagliflozin (20 mg) or dapagliflozin (10 mg) plus metformin. The primary endpoint was noninferiority of bexagliflozin to dapagliflozin for the change in glycated hemoglobin (HbA1c) from baseline to week 24. Secondary endpoints included intergroup differences in fasting plasma glucose (FPG), 2‐h‐postprandial glucose (PPG), body weight, and systolic blood pressure (SBP) from baseline to week 24. The trial also evaluated the safety profiles.ResultsThe model‐adjusted mean change from baseline to week 24 HbA1c was −1.08% for bexagliflozin and −1.10% for dapagliflozin. The intergroup difference of 0.03% (95% confidence interval [CI] −0.14% to 0.19%) was below the prespecified margin of 0.4%, confirming the noninferiority of bexagliflozin. The changes from baseline in FPG, PPG, body weight, and SBP were −1.95 mmol/L, −3.24 mmol/L, −2.52 kg, and −6.4 mm Hg in the bexagliflozin arm and −1.87 mmol/L, −3.07 mmol/L, −2.22 kg, and −6.3 mm Hg in the dapagliflozin arm. Adverse events were experienced in 62.6% and 65.0% and serious adverse events affected 4.4% and 3.5% of subjects in the bexagliflozin and dapagliflozin arm, respectively.ConclusionsBexagliflozin showed nearly identical effects and a similar safety profile to dapagliflozin when used in Chinese patients on metformin.image 10.1111/1753-0407.13526 http://creativecommons.org/licenses/by/4.0/ |
| title | Efficacy and safety of bexagliflozin compared with dapagliflozin as an adjunct to metformin in Chinese patients with type 2 diabetes mellitus: A 24‐week, randomized, double‐blind, active‐controlled, phase 3 trial |
| topic | Journal of Diabetes |
| url | https://onlinelibrary.wiley.com/doi/10.1111/1753-0407.13526 |